Fig. 2From: A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinomaComparison of the time to onset of acquired resistance. A Participants with or without ZLJT treatment. B Participants with different generations of drugs in the combination group (*P < 0.05)Back to article page